Merck, ATG005-1KT, A549 EGFRvIII Antigen Panel Cell Lines

General description
This product is a panel of two (2) genetically modified cell lines involving the EGFR gene and the tumor-sepcific EGFRvIII extracellular mutation. The panel consists of a EGFR knockout cell line (EGFR⁻/⁻) and an EGFRvIIIhigh expression cell line. The EGFR⁻/⁻cell line was generated using CompoZr® Zinc Finger Nuclease technology, and the EGFRvIIIhigh expression cell line was generated using MISSION® lentivirus. The EGFRvIIIhigh cell line expresses EGFRvIII at high levels relative to the EGFR⁻/⁻ cell line and wild type A549 cells as measured via fluorescence-activated cell sorting (FACS).

The STR profile of these cell lines match that of its parental cell line - ECACC catalog number 86012804.
Biochem/physiol Actions
Derived from a 58 year old Caucasian male. The cells can synthesise lecithin utilising the cytidine diphosphocholine pathway. Occasional cells may also contain inclusion bodies although they are not known to carry any human pathogen.
Features and Benefits
The A549 EGFRvIII antigen panel cell lines feature the EGFRvIII extracellular mutation expressed at varying levels (KO and high). These cell lines enable researchers to screen and evaluate the efficacy and potency of EGFRvIII-targeted immunotherapies in a biologically-relevant cellular research model.
Analysis Note
Tested for Mycoplasma, bacterial and fungal content, post-freeze viability, and short terminal repeat (STR) analysis for cell line identification.
Other Notes
ATG005A-1VL: A549 EGFRvIII Knockout
ATG005B-1VL: A549 EGFRvIII High
Legal Information
MISSION Use Licenses Agreement

ZFN Use Licenses Agreement
CompoZr is a registered trademark of Merck KGaA, Darmstadt, Germany
MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany